在多种产品加工过程中,花生中农药的残留变化,降解,加工因素及其在花生中农药物理化学性质之间的关系
Kai Cui1, Jian Wang1, Shuai Guan1
1Institute of Quality Standard and Testing Technology for Agro-Products, Shandong Academy of Agricultural Sciences, Shandong Provincial Key Laboratory of Test Technology on Food Quality and Safety, Jinan, Shandong 250100, People's Republic of China.
花生加工会影响农药残留. 洗和煮沸减少了残留物,而烤和炸缩了它们. 油压将杀虫剂集中在油和面粉中,影响了安全的花生消费.
科学领域:
- 食品科学 食品科学 食品科学
- 农业化学 农业化学
- 环境毒理学环境毒理学
背景情况:
- 农药残留在粮食作物中的残留物是人类健康的一个重大问题.
- 花生加工方法可以改变这些残留物的度和分布.
- 了解加工过程中的农药命运对于风险评估至关重要.
研究的目的:
- 系统地调查花生加工各个步骤中的农药残留物变化.
- 为了确定不同农药的加工因子 (PF).
- 为了将农药的物理化学特性与它们在加工过程中的行为相关联.
主要方法:
- 在加工 (剥皮,洗,煮沸,烤,炸,油压) 之前和之后对花生中的农药残留物的分析.
- 计算加工因子 (PF) 以量化残留物变化.
- 统计分析以将农药的物理化学性质 (例如,日志Kow,分子量) 与PFs相关联.
主要成果:
- 剥皮,洗和煮沸通常可以减少农药残留物 (PFs < 1).
- 烤,炸和深显示出不同的效果,其中有一些度 (PFs高达1.25).
- 油压在花生油 (PFs 1.06-2.01) 和面粉 (PFs 1.07-1.46) 中显著缩的农药.
- 农药的物理化学性质,特别是木,在沸,烤和油压过程中与PFs有很强的相关性.
结论:
- 花生加工显著影响农药残留水平,度发生在石油提取和某些方法.
- 像Log Kow这样的农药特性是它们在加工过程中的行为的主要预测因素.
- 调查结果为管理花生产品中的农药风险和促进更健康的消费提供了必要的数据.
更多相关视频
05:20Avocado Sample Preparation Using the QuEChERS Method with Ammonium Formate for Pesticide Analysis
Published on: December 8, 2023
10:24Author Spotlight: Quantification of Aflatoxins and Phytoalexins in Peanut Seeds to Identify Genetic Resistance Against Aspergillus
Published on: April 19, 2024
相关概念视频
Effects of Chemicals: Overview
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in...
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
